Cystatin c: a Biomarker of AKI in Aneurysmal Subarachnoid Haemorrhage Patients

Cystatin c as a Predictive Biomarker of Acute Kidney Injury and Neurological Outcomes in Aneurysmal Subarachnoid Haemorrhage Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06635408

Enrollment

Registered

2024-10-10

Start date

2023-10-30

Completion date

2025-01-15

Last updated

2025-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

Acute kidney injury, Delayed cerebral ischemia, Angiographic vasospasm, Aneurysmal subarachnoid hemorrhage

Brief summary

The goal of this observational study is to assess cystatin c as a predictive biomarker of early acute kidney injury in aneurysmal subarachnoid hemorrhage patients. The main question it aims to answer is: \- Does cystatin c biomarker can predict early acute kidney injury in aneurysmal subarachnoid hemorrhage patients? Participants will be grouped into Aki and Non-Aki groups based on RIFLE criteria and Cystatin c biomarker will be tested to answer the study question.

Interventions

DIAGNOSTIC_TESTcystatin c

a biomarker to assess renal function

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Patient admission to hospital within 48 hours of subarachnoid haemorrhage onset. * Subarachnoid haemorrhage caused by intracranial aneurysm rupture and is confirmed via computed tomography angiography (CTA). * Medical treatment, microsurgical clipping, or interventional endovascular treatment of aneurysm is performed within 48 hours of subarachnoid haemorrhage onset.

Exclusion criteria

* Prior onset of subarachnoid haemorrhage or other neurological diseases such as ischemic stroke, hemorrhagic stroke, or severe head trauma. * Systemic diseases, such as chronic liver diseases, chronic lung diseases, chronic heart failure, thyroid diseases and cancer. * Renal impairment at time of admission (creatinine-based eGFR less than 60 ml/min per 1.73 m2 body surface area). * Patients who are hemodynamically unstable at time of admission. * Mortality within 10 days after admission (duration of study).

Design outcomes

Primary

Measure	Time frame	Description
Acute kidney injury	6 days	stages risk and injury are considered early AKI

Secondary

Measure	Time frame	Description
Adverse neurological outcomes	10 days all except mortality within 28 days	Delayed cerebral ischemia Angiographic vasospasm Hydrocephalus Infection Mortality

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026